Loading…
We found that in Allogeneic hematopoietic stem cell transplantation (allo HSCT) patients, fiber intake significantly correlated with microbial alfa-diversity (R=0.3, p=0.01). Patients with a higher fiber diet had a significantly higher microbial alfa-diversity compared to the low fiber cohort (p<0.001)
Published associations between the gut microbiota and immune reconstitution post-Allogeneic hematopoietic stem cell transplantation (allo HSCT) are lacking. However, the gut microbiome (GM) can profoundly influence normal innate and adaptive immune development and can be altered by microbial transfer and Antibiotics (J01)
The gut microbiome composition in patients undergoing Allogeneic hematopoietic stem cell transplantation (allo HSCT) for leukemia and other blood cancers can predict treatment outcomes. The loss of diversity before transplantation is probably related to the use of broad-spectrum antibiotics, which are often prescribed for newly emerging infections during chemotherapy and radiation
There is an association between lower gut microbiota diversity and a higher risk of transplant-related death, most often due to graft-versus-host disease
Patients undergoing Allogeneic hematopoietic stem cell transplantation (allo HSCT) may experience significant changes in gut microbiota due to their underlying malignancies and exposure to extensive chemotherapy and systemic Antibiotics (J01), which may lead to different disorders
Patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) often experience significant changes in their intestinal microbiota. This is due to their underlying malignancies. The exposure to extensive chemotherapy and systemic antibiotics can lead to various disorders. Dysbiosis and increased gut permeability are common features observed in patients with GvHD.
In the context of allogenic hematopoietic stem cell transplantation (allo-HSCT), the disruption of gut microbiota diversity is associated with acute graft-versus-host disease (GvHD). GvHD causes inflammation of the liver, skin, lungs, and intestines and occurs in 40–50% of patients undergoing allo-HSCT, resulting in significant post-transplantation mortality.
Two different strategies with targeted modulation of gut microbiota, preemptive and therapeutic, have been used for preventing or treating dysbiosis in patients with Allogeneic hematopoietic stem cell transplantation (allo HSCT):
Preemptive strategies include:
*Enteral nutrition (EN)
*Prebiotics
*Probiotics
*Fecal microbiota transplantation (FMT)
*Antibiotic strategies
Therapeutic strategies include:
Microbiota can be used as a predictor of mortality in Allogeneic hematopoietic stem cell transplantation (allo HSCT)
The gut microbiome impacts the progression of tumors under chemotherapy in the context of allogeneic stem cell transplantation
The relative abundance of Actinomycetaceae was found to be significantly higher in elderly adults compared to younger ones
During the conditioning before Allogeneic hematopoietic stem cell transplantation (allo HSCT), intestinal epithelial cells (IECs) are damaged, resulting in the release of "danger signals" such as Tumor Necrosis Factor alfa (TNF-alfa) or Interleukin-1 (IL-1) / Interleukin-1 family
see also:
Allogeneic hematopoietic stem cell transplantation (allo HSCT) & Dysbiosis
Graft-Versus-Host Disease (GVHD)
Graft-Versus-Host Disease (GVHD) & Gut microbiota